MPPM9:144:19
9/04/21111/24/09
tic
y
ted
an
tion.
rela
Yes
Yes
Yes
Yes
Yes
No
No
No
tion.
with
Withdrew
ted
Corpora
consultanc
were
-determined
symptoma
a
tor
ycle.
Corpora
AEs
c
had
.
2
3
1
1
1
1
3
2
2
,Celgene
Millennium
py
le
le
le
le
le
le
le
le
gnosed
has
associa
Pharmaceuticals,
of
for
When
Cyc
Cyc
Cyc
Cyc
Cyc
Cyc
Cyc
Cyc
Celgene
and
these
investiga
dia
regimen.
R.N.
by
tion
;USA
of
to
thera
also
this
Bureau
to
newly
of
Millennium
NY
due
y
tion
was
funded
some
Corpora
T-BiRD
completion
ted
No
No
No
No
of
tion,
stud
(RAE)
Yes
Yes
Yes
Yes
use
Therapy
to
Speakers
ork,
,this
(AE);
on
Rela
medica
Medica
tment
the
Pharmaceuticals.
Y
Celgene
withdrew
pidly
of
Corpora
prior
for
of
event
py
trea
ttack.
ra
2006;97:457-63.
2
1
1
1
1
1
1
1
long-term
Excerpta
tients
a
New
continued
the
response.
PR
member
Millennium
Celgene
pa
Bureau
thera
Number
lude
from
a
myeloma
for
a
for
but
Immunol.
is
adverse
from,
ischemic
prec
1999;11:121-32.
an
T-BiRD
AEs,
2
4
3
3
2
3
1999;103:1031-5.
and
3).
support
Speakers
Grade
profound
Asthma
3).
regimen
y
funding
achieved
tmay
Agents.
from,
the
able
Hospital,
yCommittee
transient
and
of
able
(T
progressive
Allerg
Immunol.
started
serious
TIA,
pid
tha
(T
of
events.
tients
le
2008;111:1101-9.
funding
AEs
ra
Ann
research
effective
yClin
Advisor
experienced
who
had
syndrome
al.
Antimicrob
member
editorial/printing
ted
died
thy
ypa
profi
Blood.
the
a
(RAE)
et
J
Allerg
is
tion
al.
research
of
highly
M,
J
Int
received
(50%)
(33%)
(17%)
thrombosis;
a
et
(6%)
Adverse
man
al.
and
esbyterian
al.
ydrug
event
brilla
is
tachieves
R,
received
es
has
myopa
3.
et
et
failure
pain
fi
member
Pr
tients
tients
tment-rela
tients
tient
rash
3
tha
ences
AA,
received
1
DA,
a
,and
stud
1
pa
pa
pa
pa
able
,deep-vein
onseca-Aten
ost
authors
T
Adverse
Skin
Stevens-Johnson
TIA
Renal
Chest
Steroid
DVT
Atrial
.has
is
for
Proteolix;
9
to
6
trea
3
1
CONCLUSIONS
T-BiRD
MM
Although
adverse-event
ork
Niesvizky
F
F
Khan
Safety
·
·
·
·
DVT
·
·
Refer
1.
2.
3.
4.
Acknowledgments
The
Disclosur
M.T
M.C.
role
and
Pharmaceuticals.
Y
wn
New
6
sho
Niesvizky
is
Cycle
18).
and
ycle
=
5
(VGPR)
c
(N
disease.
(%)
,Ruben
n
(61)
(28)
(11)
(33)
(56)
(11)
(42)
(17)
(25)
(25)
Cycle
of
Dexamethasone)
2
teach
5
2
6
2
5
2
3
3
11
10
response
a
tients,a
System.
4
P
],
University
PR.
ging
Cycle
1­6).
Sta
nell
partial
progression
abnormalities
®
baseline
3
tional
(range
had
Chen-Kiang
Cor
ygood
.
Cycle
5.5
achieved
from
of
ver
(6%)
Interna
was
had
ISS,
2
cytogenetic
CR
tients
tion;
therapy
,Selina
Cycle
ycles
pa
and
1
c
(67%)
M-protein
d
College
achieved
18
-BiRD
1
Myeloma
tients
achieved
of
hybridiza
T
T-BiRD
1
stage
pa
had
situ
to
Cycle
residual
of
had
in
18
MM
of
.Leonar
of
(55%)
T-BiRD,
ge
P
Medical
y
12
(14%)
of
FISH*
eill
number
Baseline
tients
by
uorescence
Response
ycle,
ycles:
fl
pa
tients
ycles
2.
Baseline
2.
[Revlimid
,W
c
c
c
2.
abnormality
0
pa
percenta
(Durie-Salmon)
(ISS)
e
,John
FISH,
75
50
25
median
1
5
6
igure
ge
ge
100
1
F
12.
baseline
from
M-protein
residual
of
percentage
Mean
10/18
1/7
able
The
After
After
­
­
After
Mean
in
T
Sta
Ia
IIa
IIIa
Sta
I
II
III
Abnormality
del(13q14)
t(11;14)
Hyperdiploid
No
=
Figur
Outcomes
·
·
·
·
·
*n
Crann
of
Pathology
tions
Multiple
of
28
Common
(received
,Mary
progression
1
determina
enrollment
Institute
disease
analysis
3.0.
(44­82)
(55.6)
(1.2­7.6)
(2.2­7.9)
(92­280)
(9.1­15.4)
(100­383)
(0.7­1.5)
(8.1­9.9)
rm
for
Manco
Department
planned
light-chain
Cancer
62
10
2.2
3.4
0.9
9.0
C.
2
153
224
;
confi
version
12.3
18).
to
the
vailable
free
=
tional
NY
2)
a
(N
and
done
Na
were
,Megan
ork,
tion
reaching
the
and
2
Y
xa
were
to
(NCI-CTCAE)
1
18
22
Ely
ging
until
and
New
21
Dexamethasone
ima
Events
ables
Lenalidomide
far
(T
characteristics
accrue
according
(range)
thus
],
,Scott1
skeletal
to
Adverse
(range)
(range)
(range)
es
graded
regimen).
median
(range)
and
for
patient
(range)
®
Hospital,
.
Zafar
enrolled
(range)
were
TS
median
median
ve
T-BiRD
mg/L,
(range)
Symptomatic
electrophoresis/immunofi
median
biopsy
continues
median
median
w
L,
yCriteria
ha
g/dL,
measur
monthly
response.
the
characteristics
median
mg/dL,
Baseline
of
events
of
g/dL,
median
K/
mg/dL,
,Faiza
protein
dehydrogenase.
tients
(%)
1.
1
te
esbyterian
done
marro
tients.
protocol
day
years,
n
U/L,
tinine,
in
depth
pa
pa
1
-Microglobulin,
telets,
2
lacta
5
Pr
able
Serum
were
Bone
or
This
25
Adverse
Terminolog
RESUL
21
T
Age,
Male,
Albumin,
LDH,
Hemoglobin,
Pla
Crea
Calcium,
Outcome
·
·
·
·
Baseline
·
LDH,
ork
Pearse
Dexamethasone
Y
with
had
safety
enhance
.
and
[Biaxin
New
,Roger1
corticosteroid
yto
achieved
trimethoprim
toxicity
ycle
Use
and
dexamethasone
ter
ydifferent
tr
c
mg,
+
ver
to
grea
ve
tment-naive,
trial
response
800
to
ha
additional
28-day
ycle
daily
trea
c
.
and
mg
ont Jayabalan
py
T-BiRD
each
University
1):
of
S.
100
lenalidomide
leading
gnosed,
28-day
81
thera
2
yeffect
imposing
22
nell
thalidomide
igure
the
2­4
tion
tor
dia
(F
15,
each
sulfamethoxazole
omycin
Dexamethasone
Cor
gent
and
phase
of
,David
without
ws
8,
thereafter
daily
1
ya
1,
the
newly
of
follo
1­21
enhance
tor
combina
in
criteria.
1­7;
(PCP):
dexamethasone,
as
days
daily
Upfr
to
ywere
daily
inhibitor
of
on
days
days
ted
,lenalidomide
BiRD
immunomodula
thalidomide
on
daily
stud
on
tablet
College
daily
Coleman
successful
to
twice
pneumonia
)1
mg
®
egimen.
learance
daily
similar
overall
adding
criteria
this
Durie-Salmon
mg
81
administered
mg
daily
for
r
postula
c
immunomodula
DS
added
the
by
in
by
40
mg
mg
proton-pump
is
tic
was
500
25
carinii
50
aspirin
Medical
by
weak
permitting
MM
py
-BiRD
,Morton
a
was
upon
luded
1
tic
ystis
(Bactrim
T
tion
hepa
1
eill
as
structurally
thus
regimen
inc
y.
eligibility
thera
1.e
wing
mg
les,
Clarithr
W
slo
exposure
BiRD
larithromycin
Mark
acting
cac
tientsa
c
dexamethasone
lenalidomide
thalidomide
Pneumoc
160
thrombosis:
gastrointestinal:
Day
Dexamethasone
Lenalidomide
Thalidomide
Clarithromycin
2009.
Clarithromycin
combina
­
­
Although
profi
Thalidomide
effi
OBJECTIVE
Toimprove
the
METHODS
P
symptoma
reatment
T-BiRD
­
­
­
­
Prophylaxis
­
­
Figur
·
·
·
·
Patient
·
T
·
·
­
5­8,
],
omer
®
T
72
of
ted
of
25
to
leg
pid
lude
(PR),
trial
and
with
tients
tients
tient
with
in
were
renal
ra
Myeloma,
w-dose
trial
Serum
of
­81%,
overall
during
phase
December
increase
A
initia
dose
disease
pa
median
pa
adverse
pa
the
prior
for
90.3%;
lo
ycle,
4
because
full-dose
prec
a
c
ta
tions
response
rm
a
withdrew
1
12
,the
an
of
of
tients
in
USA;
and
[Revlimid
of
was
larithromycin
a
to
ycle
py
may
event.
(PR),
response
safely
c
c
55%
tion
luded
pa
LA,
myeloma
dexamethasone)
subjects.
of
confi
(39%)
developed
enrollment
1­6).
partial
myeloma
regimen
toxicities.
],
(MM)
28-day
given
all
to
evaluable
thera
was
syndrome)
1
inc
could
®
a
T-BiRD
partial
addition
single-institution
is
initia
for
determina
for
te
­79%,
of
2,
adverse
(MM)
Orleans,
a
a
of
thrombosis
(range
compared
3
ygood
ra
experienced
to
rst-line
an
response
multiple
twe
the
pping
in
Thromboprophylaxis
done
ycle
consists
22
.
subjects
fi
from
New
used
planned
1,
ycles
ver
7
c
ymphoma
lenalidomide
tic
tha
myeloma
a
5.5
ycle
c
prior
toxicities
],
tleast
[Revlimid
15,
were
ycle
c
5
a
better
(56%)
in
progressive
]/dexamethasone)
L
®
with
a
daily
myeloma
®
8,
was
light-chain
was
c
M-protein
of
or
partial
y(ASH),
tion
enrolled
Thalidomide
with
in
tment.
rash
ttack
Toxicity
Other
deep-vein
for
non-overla
regimen
mg
ging
by
effective
multiple
1,
(Stevens-Johnson
a
died
experienced
tes:
tolog
ve
ycle.
days)
free
ycles
­77%,
3.
VGPR
trea
skin
with
[Biaxin
symptoma
tic
were
ima
c
drop
2
received
achieving
subjects
days
c
t100
as
(PR)
2
ra
ycle
highly
multiple
in
achieved
ha
accrue
rash
tients
[Revlimid
Hema
ehypothesized
lenalidomide
T-BiRD
a
ycle
the
10
c
tient
a
tic
of
py
W
combina
],
on
to
who
subject
myeloma.
®
tients
well
c
of
during
ischemic
in
is
pa
90%
The
T-BiRD
grade
skin
1
drugs
pa
pa
mg
28-day
skeletal
percent
subject
BiRD
subsequent
as
of
1
4
1
response
thera
(CR).
symptoma
a
response
total
Society
18
40
tbasis,
(RAE),
had
pain
tion.
Excellence
larithromycin
over
[Biaxin
of
on
tion
and
.A
T-BiRD
multiple
the
MM.
of
­61%,
these
thereafter
Mean
subjects
but
2
enrolled
1
(Thalidomide,
tic
xa
continues
1
9
ted
grade
transient
symptoma
(RAE),
brilla
in
]/lenalidomide
of
(c
tof
mg
all
the
tment
and
number
partial
or
a
chest
fi
®
American
py
upfront
1­21
a
ycle
F
thy
results:
response
since
,81
biopsy
BiRD.
toxicity
rela
had
Methods:
w
c
toxicity:
trial
lusions:
yof
38.9%.
the
as
trea
with
had
gnosed
impressive
y.
for
to
days
week
protocol
ws:
tient
1
a
of
ybenefi
larithromycin
tleast
intent-to-trea
response
man
dia
[Biaxin
thera
symptoma
rst
median
­92%.
y-drug
drug
Conc
Center
use
cac
due
myopa
(CR),
1
tor
c
for
weekly
fi
marro
This
a
ycles
6
an
pa
developed
with
complete
regimen,
,dexamethasone
for
The
c
follo
100%,
to
1
tment
yielded
for
upfront
effi
wal
(RAE),
1
meeting
impressive
in
2
stud
ycle.
since
in
py
mg
the
once
as
ycle
.On
1,
tient
c
newly
BiRD
the
CR.
c
and
daily
of
25
.Bone
is
was
ydue
steroid
1
72)
for
pa
trea
use
in
51st
40%
to
use
mg
or
te
(RAE),
ycle
2
in
=
response
thera
achieved
some
T-BiRD
Results:
ycle
better
withdra
1
larithromycin
tthe
yielded
time
ra
stud
c
(n
(thalidomide,
for
twice
-BiRD
a
daily
(162
electrophoresis/immunofi
c
­93%,
or
of
tment
(c
py
safety
in
monthly
had
5
tient
(AE),
the
1
and
T
ABSTRACT
nearly
mg
grade
tients
immunomodula
profound
trial
test
T-BiRD
mg
tients.
pa
long-term
BACKGROUND
Trea
BiRD
2
complete
11
Background:
dexamethasone)
pa
with
the
thalidomide
T-BiRD
thera
to
of
500
lenalidomide
50
aspirin
protein
done
progression
pa
(67%)
response
ateach
cycle
response
(VGPR)
of
event
from
thalidomide
cycle
failure
with
(RAE),
completion
and
its
·
d
Presented
d
r.intesop_DiRB_TT_BiRD_poster.indd9510390SS0930159

---